查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1975308

全球遺傳性血管性水腫治療市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Hereditary Angioedema Therapeutics Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 133 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計遺傳性血管性水腫治療的市場規模將從 2025 年的 47.3 億美元成長到 2034 年的 91.8 億美元，2026 年至 2034 年的複合年成長率為 7.66%。

由於人們對遺傳性血管性水腫 (HAE) 的認知不斷提高，以及診斷能力的提升，全球 HAE 治療市場正穩步成長。遺傳性血管性水腫是一種罕見的遺傳性疾病，需要標靶治療，而生物製藥和血漿衍生療法的進步已顯著改善了患者的治療效果。此外，病患支援活動的拓展和專科醫療中心就診管道的改善也促進了市場成長。

市場成長主要受持續的臨床研究、新治療方法的監管核准以及醫療保健支出增加的推動。製藥公司正大力投資創新治療方法，包括單株抗體和基因療法。此外，已開發國家優惠的健保政策也有助於提高病患獲得先進治療的機會。

隨著在研發線產品和精準醫療方法日益受到關注，未來前景樂觀。長效和可自行給藥治療方法的開發有望提高患者的用藥便利性和依從性。隨著全球宣傳宣傳活動和基因篩檢工作的擴展，遺傳性血管性水腫治療市場有望持續穩定成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球遺傳性血管性水腫療法市場：依治療方法

  • 市場分析、洞察與預測
  • C1酯酶抑制劑
  • 緩激肽B2受體拮抗劑
  • 激肽釋放酶抑制劑
  • 其他

第5章 全球遺傳性血管性水腫治療藥物市場：依最終用途分類

  • 市場分析、洞察與預測
  • 預防性治療
  • 一經請求

第6章 全球遺傳性血管性水腫療法市場：依給藥途徑分類

  • 市場分析、洞察與預測
  • 靜脈注射
  • 皮下注射
  • 口服

第7章 全球遺傳性血管性水腫治療藥物市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 亞太其他地區
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第8章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第9章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • BioCryst Pharmaceuticals Inc
    • Ionis Pharmaceuticals
    • CSL
    • Attune Pharmaceuticals
    • Adverum Biotechnologies Inc
    • KalVista Pharmaceuticals Inc
    • Takeda Pharmaceutical Company Limited
    • Pharming
簡介目錄
Product Code: VMR112112397

The Hereditary Angioedema Therapeutics Market size is expected to reach USD 9.18 Billion in 2034 from USD 4.73 Billion (2025) growing at a CAGR of 7.66% during 2026-2034.

The Global Hereditary Angioedema Therapeutics Market is experiencing consistent growth due to increasing awareness and improved diagnostic capabilities. Hereditary angioedema (HAE) is a rare genetic disorder requiring targeted treatment approaches, and advancements in biologics and plasma-derived therapies have significantly improved patient outcomes. Growing patient advocacy and better access to specialized care centers are also contributing to market expansion.

Market growth is driven by ongoing clinical research, regulatory approvals for novel therapies, and rising healthcare expenditure. Pharmaceutical companies are investing heavily in innovative treatments, including monoclonal antibodies and gene-based therapies. Additionally, favorable reimbursement policies in developed economies are enhancing patient access to advanced therapeutics.

Future prospects are optimistic as pipeline products and precision medicine approaches gain traction. The development of long-acting and self-administered therapies is expected to improve patient convenience and adherence. As awareness campaigns and genetic screening initiatives expand globally, the hereditary angioedema therapeutics market is likely to achieve sustained and progressive growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Treatment

  • C1-Esterase Inhibitor
  • Bradykinin B2 Receptor Antagonist
  • Kallikrein Inhibitor
  • Others

By End-use

  • Prophylaxis
  • On-Demand

By Route of Administration

  • Intravenous
  • Subcutaneous
  • Oral

COMPANIES PROFILED

  • BioCryst Pharmaceuticals Inc, Ionis Pharmaceuticals, CSL, Attune Pharmaceuticals, Adverum Biotechnologies Inc, KalVista Pharmaceuticals Inc, Takeda Pharmaceutical Company Limited, Pharming
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET: BY TREATMENT 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Treatment
  • 4.2. C1-Esterase Inhibitor Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Bradykinin B2 Receptor Antagonist Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Kallikrein Inhibitor Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET: BY END-USE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast End-use
  • 5.2. Prophylaxis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. On-Demand Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Route Of Administration
  • 6.2. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Subcutaneous Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Treatment
    • 7.2.2 By End-use
    • 7.2.3 By Route Of Administration
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Treatment
    • 7.3.2 By End-use
    • 7.3.3 By Route Of Administration
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Treatment
    • 7.4.2 By End-use
    • 7.4.3 By Route Of Administration
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Treatment
    • 7.5.2 By End-use
    • 7.5.3 By Route Of Administration
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 South East Asia
    • 7.5.9 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Treatment
    • 7.6.2 By End-use
    • 7.6.3 By Route Of Administration
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 BioCryst Pharmaceuticals Inc
    • 9.2.2 Ionis Pharmaceuticals
    • 9.2.3 CSL
    • 9.2.4 Attune Pharmaceuticals
    • 9.2.5 Adverum Biotechnologies Inc
    • 9.2.6 KalVista Pharmaceuticals Inc
    • 9.2.7 Takeda Pharmaceutical Company Limited
    • 9.2.8 Pharming